Source : Diabetologia Auteur : Cariou et al.


Aims/hypothesis Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown.

Source : Diabetes & Metabolic Syndrome: Clinical Research & Reviews Auteur : Ian Huang and al.
ABSTRACT Background and aims: Diabetes Mellitus (DM) is chronic conditions with devastating multi-systemic complication and may be associated with severe form of Coronavirus Disease 2019 (COVID-19). We conducted a systematic review and meta-analysis in order to investigate the association between DM and poor outcome in patients with COVID-19 pneumonia.

Source : AHA

Auteur : Naveed Sattar and al.


The Coronavirus Disease 2019 (COVID-19) pandemic has led to worldwide research efforts to identify people at greatest risk of developing critical illness and dying. Initial data pointed towards older individuals being particularly vulnerable, as well as those with diabetes or cardiovascular (including hypertension), respiratory or kidney disease. These problems are often concentrated in certain racial groups (e.g. African Americans and Asians) which also appear to be more prone to worse COVID-19 outcomes.

Télécharger l’article complet

Source : ORCID

Auteur : Austin R. Morrison and al.

Letter to the Editor :

“Une « Letter to the Editor » concernant 2 patients avec forme  respiratoire sévère de Covid chez qui l’utilisation de Tocilizumab s’est accompagnée d’une Hypertriglycéridémie majeure. Donc surveillance métabolique rigoureuse à prévoir dans cette indication.” proposé par le Dr Laurent MEYER.

Abstract :

Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19.

Télécharger l’article complet

Source : Journal of Diabetes Science and Technology Auteur : Bruce Bode and al.


“Un article intéressant sur les liens Diabète et Covid aux USA. Il s’agit d’un travail rétrospectif dont les résultats laissent à penser que l’importance de l’hyperglycémie au moment de l’infection par Covid joue un rôle majeur dans la surmortalité des diabétiques et qu’il est donc indispensable de contrôler au mieux les glycémies le plus tôt possible après les premiers symptômes.” un article proposé par le Dr Laurent MEYER.

Source : JAMA Network

Auteur : Rita Rubin

Medical News & Perspectives

Suzanne Watnick, MD, got the call at 9PM Friday, February 28. Aman in his 50s who received dialysis treatments at a Northwest Kidney Centers facility in Seattle was the first person with coronavirus disease 2019 (COVID-19) to die in the United States. Watnick, the nonprofit dialysis organization’s chief medical officer, immediately called Elizabeth McNamara, RN, vice president of patient care services and chief nursing officer. The patient had last undergone dialysis at one of Northwest Kidney Centers’ 19 sites a week earlier.

Télécharger l’article complet

16 avril 2020 Recommandations

Source : HAS  

Continuité de la prise en charge des patients atteints d’hépatites virales chroniques

  • Réponse rapide n°1 : Les patients atteints de cirrhose au stade B ou C de la classification de Child-Pugh sont à risque de développer une forme grave de COVID-19.
  • Réponse rapide n°2 : Réaliser le suivi des patients atteints d’hépatite chronique au maximum hors des établissements de soins et privilégier la téléconsultation en veillant à l’absence de rupture de suivi.

© Les Hôpitaux Universitaires de Strasbourg 2020 - Tous droits réservés